A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel three-arm, and single-dose Phase I clinical
study, designed to compare the similarity of pharmacokinetics, safety and immunogenicity
between BAT2506 Injection and Simponi® (EU-licensed and US-licensed) after single
subcutaneous administration in healthy Chinese male subjects.